Publication date: Jul 16, 2019
The purpose of this research study is to see whether using atezolizumab before surgery is safe and does not cause side effects that delay surgery in participants with cutaneous melanoma that has not spread to other areas of the body (non-metastatic) and can be removed by surgery (resectable) but has a higher risk of coming back after surgery (high-risk).
|drug||DRUGBANK||Hepatitis B Vaccine (Recombinant)|
- Adjuvant Treatment Determined By Pathological Response To Neoadjvuant Nivolumab
- Ultrasound, CT, MRI, or PET-CT for staging and re-staging of adults with cutaneous melanoma.
- A Phase II Study of the Interleukin-6 Receptor Inhibitor Tocilizumab in Combination With Ipilimumab and Nivolumab in Patients With Unresectable Stage III or Stage IV Melanoma